Head-to-head evidence
HLX04-O vs KSI-301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
HLX04-O
Developed by Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
The trial randomized 410 participants to HLX04-O or the active comparator ranibizumab and masked both participants and investigators. Its primary clinical endpoint was the mean change in best-corrected visual acuity at Week 36, but no statistical comparison or outcome result is available yet.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX04-O's landscape · KSI-301's landscape